Lung Transplantation - Pipeline Review, H1 2016

Global Markets Direct’s, ‘Lung Transplantation - Pipeline Review, H1 2016’, provides an overview of the Lung Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lung Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lung Transplantation and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape of Lung Transplantation
• The report reviews pipeline therapeutics for Lung Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Lung Transplantation therapeutics and enlists all their major and minor projects
• The report assesses Lung Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Lung Transplantation

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Lung Transplantation
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Lung Transplantation pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lung Transplantation Overview 6
Therapeutics Development 7
Pipeline Products for Lung Transplantation - Overview 7
Lung Transplantation - Therapeutics under Development by Companies 8
Lung Transplantation - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Lung Transplantation - Products under Development by Companies 11
Lung Transplantation - Companies Involved in Therapeutics Development 12
Apeptico Forschung und Entwicklung GmbH 12
Kamada Ltd. 13
Proteo, Inc. 14
Quark Pharmaceuticals, Inc. 15
Lung Transplantation - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
alpha-1 proteinase inhibitor (human) - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
FX-06 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PB-01 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
QPLI-1 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
R-503 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
R-801 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
solnatide - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
tiprelestat - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Lung Transplantation - Recent Pipeline Updates 42
Lung Transplantation - Dormant Projects 49
Lung Transplantation - Product Development Milestones 50
Featured News & Press Releases 50
Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 50
Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 51
Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs 52
Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation 53
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 53
Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Number of Products under Development for Lung Transplantation, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Lung Transplantation - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2016 12
Lung Transplantation - Pipeline by Kamada Ltd., H1 2016 13
Lung Transplantation - Pipeline by Proteo, Inc., H1 2016 14
Lung Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 15
Assessment by Monotherapy Products, H1 2016 16
Number of Products by Stage and Target, H1 2016 18
Number of Products by Stage and Mechanism of Action, H1 2016 20
Number of Products by Stage and Route of Administration, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 24
Lung Transplantation Therapeutics - Recent Pipeline Updates, H1 2016 42
Lung Transplantation - Dormant Projects, H1 2016 49

List of Figures

Number of Products under Development for Lung Transplantation, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Assessment by Monotherapy Products, H1 2016 16
Number of Products by Targets, H1 2016 17
Number of Products by Stage and Targets, H1 2016 17
Number of Products by Mechanism of Actions, H1 2016 19
Number of Products by Stage and Mechanism of Actions, H1 2016 19
Number of Products by Routes of Administration, H1 2016 21
Number of Products by Stage and Routes of Administration, H1 2016 21
Number of Products by Molecule Types, H1 2016 23
Number of Products by Stage and Molecule Types, H1 2016 23